|
Kadri S, Lee J, Fitzpatrick C. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials.
COVID-19 is an emerging, rapidly evolving situation. | All recommendations are category 2A unless otherwise noted. Median PFS and OS were 5 and 11 months, respectively.38 Treatment-related grade ≥3 adverse events were reported in 60% of patients. The workup of patients with Richter's transformation or progression is similar to that of patients with CLL/SLL and should include history and physical examination with attention to node-bearing areas, including Waldeyer ring, and the size of liver and spleen; whole-body PET/CT scan; or chest/abdominal/pelvic CT with contrast of diagnostic quality. In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Haematologica 2010;95:1526–1533. In a phase I/II trial that included 20 patients with Richter's transformation, OFAR (with increasing doses) resulted in an ORR of 50%.32 The median response duration was 10 months. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071. Hemorrhage:Fatal bleeding events have occurred in patients who received IMBRUVICA®. Younes A, Brody J, Carpio C. Safety and efficacy of the combination of ibrutinib and nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia [abstract]. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. J Natl Compr Canc Netw. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
PharmacistsNCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. Hematol Oncol. The panel acknowledged that there are limited published data supporting the use of nivolumab and pembrolizumab in patients with Richter's transformation refractory to chemoimmunotherapy or in those with a del(17p)/TP53 mutation, and that additional data will be forthcoming. Please enable it to take advantage of the complete set of features! This activity is supported by educational funding provided by Amgen. 1 CLL remains the most prevalent adult leukemia in Western countries. Parikh SA, Rabe KG, Call TG. Nursing (ANCC): NCCN designates this educational activity for a maximum of 1.0 contact hour. Epub 2015 Dec 24. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial.
Kadri S, Lee J, Fitzpatrick C. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials.
COVID-19 is an emerging, rapidly evolving situation. | All recommendations are category 2A unless otherwise noted. Median PFS and OS were 5 and 11 months, respectively.38 Treatment-related grade ≥3 adverse events were reported in 60% of patients. The workup of patients with Richter's transformation or progression is similar to that of patients with CLL/SLL and should include history and physical examination with attention to node-bearing areas, including Waldeyer ring, and the size of liver and spleen; whole-body PET/CT scan; or chest/abdominal/pelvic CT with contrast of diagnostic quality. In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Haematologica 2010;95:1526–1533. In a phase I/II trial that included 20 patients with Richter's transformation, OFAR (with increasing doses) resulted in an ORR of 50%.32 The median response duration was 10 months. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071. Hemorrhage:Fatal bleeding events have occurred in patients who received IMBRUVICA®. Younes A, Brody J, Carpio C. Safety and efficacy of the combination of ibrutinib and nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia [abstract]. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. J Natl Compr Canc Netw. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
PharmacistsNCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. Hematol Oncol. The panel acknowledged that there are limited published data supporting the use of nivolumab and pembrolizumab in patients with Richter's transformation refractory to chemoimmunotherapy or in those with a del(17p)/TP53 mutation, and that additional data will be forthcoming. Please enable it to take advantage of the complete set of features! This activity is supported by educational funding provided by Amgen. 1 CLL remains the most prevalent adult leukemia in Western countries. Parikh SA, Rabe KG, Call TG. Nursing (ANCC): NCCN designates this educational activity for a maximum of 1.0 contact hour. Epub 2015 Dec 24. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial.